Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $27
Morgan Stanley maintains Adagene (NASDAQ:ADAG) with a Overweight and lowers the price target from $33 to $27.
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
54 Biggest Movers From Yesterday
Gainers
Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
Adagene Presents Clinical Data Co Says Demonstrates Strong Safety, Early Signals Of Efficacy In Cold Tumors Including Pancreatic And Ovarian Cancers For Anti-CTLA-4 Monoclonal Antibody, ADG116, At ESMO-IO 2021
Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today
Adagene Reports Collab For Trial Of ADG106 In Combo With Nivolumab In Patients With Non-Small Cell Lung Cancer In Singapore
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -
- ADG106 now
Adagene Inks Third Cancer Trial Collaboration With Merck
Adagene Inc (NASDAQ:ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK). The agreement includes…